By: Rasmus Kragh Jakobsen
Big news for CRISPR and safe genetherapy! First data from CRISPR-based therapies to treat sickle cell disease and beta thalassemia shows promising results. Still early days though.
The ins and outs of base editors. Excellent feature by Sandeep Ravindran, Nature
»Highly abundant, previously untapped type I CRISPR–Cas systems can be harnessed for genome engineering applications in eukaryotic cells«, Nature Biotechnology
Press release on the study by Caribou
A moratorium on heritable human genome editing is not enough argues Jennifer Doudna in Science one year after chinese CRISPR babies
Russian consensus that human genome editing on embryos and germ cells is premature, 15 geneticists, clinicians and bioethicists writes in a letter to Nature.
Gene therapy global boom, $2 billion spending spree in production facilities for future gene therapies
And speaking of when things went awry: Where is He? AP News takes a look at the fate of He Jiankui and the CRISPR babies 1 year after He shocked the world. It's a mystery. No one seems to have heard from him or them since early 2019.